Liliana Bustamante, MD

home / authors / liliana-bustamante-md

Liliana Bustamante, MD, is a medical oncologist and hematologist at Florida Cancer Specialists & Research Institute

Articles

Liliana Bustamante, MD, medical oncologist, hematologist, Florida Cancer Specialists & Research Institute; Jessica Stine, MD, medical director, Gynecologic Oncology, Florida Cancer Specialists & Research Institute

Peer Support, Adaptability, and Self-Confidence Are Hallmarks of Successful Oncology Careers: With Liliana Bustamante, MD; and Jessica Stine, MD

Liliana Bustamante, MD;Jessica Stine, MD
April 10th 2025

Drs Bustamante and Stine discuss their journeys toward oncology careers, the importance of peer mentorship, and the evolving nature of work-life balance.

Read More

Latest Updated Articles

Bridging Data and Expert Insights: Paving the Way for Improved CLL Outcomes
Published: March 10th 2025 | Updated: April 25th 2025
Bridging Data and Expert Insights: Paving the Way for Improved CLL Outcomes
Núria Agustí Garcia, MD
Published: April 21st 2025 | Updated: April 23rd 2025
Dr Agustí on Patient Eligibility for Evaluating Chemoradiotherapy vs Radiotherapy Alone in Intermediate-Risk Cervical Cancer
Prognostic and predictive role of circulating tumor DNA (ctDNA) in stage III colon cancer treated with celecoxib: Findings from CALGB (Alliance)/SWOG 80702
Published: April 16th 2025 | Updated: April 18th 2025
Prognostic and Predictive Role of Circulating Tumor DNA (ctDNA) in Stage III Colon Cancer Treated With Celecoxib: Findings from CALGB (Alliance)/SWOG 80702
Genotype-Directed Therapies for HR+/HER2– Advanced Breast Cancer
Published: February 18th 2025 | Updated: April 17th 2025
Genotype-Directed Therapies for HR+/HER2– Advanced Breast Cancer
Real-world comparison of the efficacy and safety of atezolizumab versus durvalumab in extensive-stage small cell lung cancer
Published: December 17th 2024 | Updated: March 26th 2025
Real-world comparison of the efficacy and safety of atezolizumab versus durvalumab in extensive-stage small cell lung cancer
RLY-2608
Published: January 22nd 2025 | Updated: February 14th 2025
Efficacy of RLY-2608, a mutant-selective PI3Kα inhibitor, in patients with PIK3CA-mutant HR+HER2- advanced breast cancer: ReDiscover trial